Xavier Vela Parada, MD
Nephrology · Worcester, MANPI 1598269896
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Calliditas Therapeutics US Inc. accounts for 62.8% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $4,034, more than ten times the $110 reported in 2022.
Across 36 payments — averaging $180.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$4K
- Mozarc Medical US LLC$576
- Bayer$448
- Medtronic$339
- AstraZeneca$257
- Amgen$205
- plus $589 from 6 others
What the payments were for
- Consulting fees$2,25035%
- Travel & lodging$1,49323%
- Food & beverage$2,74842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 9 | $4,077 |
| Mozarc Medical US LLC | 6 | $576 |
| Bayer | 3 | $448 |
| Medtronic | 1 | $339 |
| AstraZeneca | 3 | $257 |
| Amgen | 2 | $205 |
| Novartis | 2 | $163 |
| Cormedix Inc. | 2 | $115 |
| Otsuka America Pharmaceutical, Inc. | 1 | $92 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $89 |
| Apellis Pharmaceuticals, Inc. | 2 | $74 |
| Fresenius USA Marketing, Inc. | 2 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,491 in reported general payments places this provider in the 80th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 13 | $38 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Worcester
- Anil ChandrakerWorcester$162K
- Matthew TrainorWorcester$26K
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Michael GermainSpringfield$443K
- Rekha AbichandaniCambridge$442K
- Leslie FangBoston$388K
- Nicolaos AthienitesBrockton$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.